Meningococcal serogroup B disease in Turkey A guess or reality?

被引:1
|
作者
Bakir, Mustafa [1 ]
机构
[1] Marmara Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, Istanbul, Turkey
关键词
invasive; meningococcal; diseases; epidemiology; serogroup B; Turkey; surveillance; vaccine; BACTERIAL-MENINGITIS; EPIDEMIOLOGY;
D O I
10.4161/hv.28438
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Each country chooses the appropriate vaccine against IMD depending on the locally prevalent serogroups of N. meningitides. Frequency of each meningococcal serogroup varies considerably over time and by geographical location. Despite the majority of IMD cases (85%) are caused by serogroups B and C in Europe, true prevalence of serogroup B IMD cases in Turkey is unclear. In one of the recent studies, the sharp decrease of serogroup B IMD from 35% down to 2.5% in a few years despite the absence of vaccination is confusing. Millions of European Turkish people travels from Europe to Turkey every year who could most probably carry serogroup B. It is obvious that a nationwide active surveillance is crucial to assess the the true epidemiology and burden of IMD which has a major impact on the choice of vaccine type and age interval the vaccination to be implemented.
引用
收藏
页码:1721 / 1724
页数:4
相关论文
共 50 条
  • [21] Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France
    Lecocq, Heloise
    du Chatelet, Isabelle Parent
    Taha, Muhamed-Kheir
    Levy-Bruhl, Daniel
    Dervaux, Benoit
    VACCINE, 2016, 34 (19) : 2240 - 2250
  • [22] Clinical experience with the meningococcal B vaccine, Bexsero®: Prospects for reducing the burden of meningococcal serogroup B disease
    Watson, Philip S.
    Turner, David P. J.
    VACCINE, 2016, 34 (07) : 875 - 880
  • [23] Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada
    Tu, Hong Anh T.
    Deeks, Shelley L.
    Morris, Shaun K.
    Strifler, Lisa
    Crowcroft, Natasha
    Jamieson, Frances B.
    Kwong, Jeffrey C.
    Coyte, Peter C.
    Krahn, Murray
    Sander, Beate
    VACCINE, 2014, 32 (42) : 5436 - 5446
  • [24] Immunization for meningococcal serogroup B: What does the practitioner need to know?
    Robinson, Joan L.
    PAEDIATRICS & CHILD HEALTH, 2014, 19 (02) : 91 - 94
  • [25] Global epidemiology of serogroup Y invasive meningococcal disease: a literature review
    Htar, Myint Tin Tin
    Findlow, Jamie
    Balmer, Paul
    Swerdlow, David
    EPIDEMIOLOGY & INFECTION, 2024, 152 : e157
  • [26] Meningococcal serogroup Y emergence in Europe Update 2011
    Broeker, Michael
    Jacobsson, Susanne
    Kuusi, Markku
    Pace, David
    Simoes, Maria J.
    Skoczynska, Anna
    Taha, Muhamed-Kheir
    Toropainen, Maija
    Tzanakaki, Georgina
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (12) : 1907 - 1911
  • [27] An effective serogroup B meningococcal vaccine
    Dominguez, Francisco
    Menendez, Jorge
    Ochoa, Rolando
    VACCINE, 2006, 24 (49-50) : 7025 - 7026
  • [28] The difficult road to new vaccines for pertussis and serogroup B meningococcal disease
    Gorringe, Andrew R.
    JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY, 2016, 91 (01) : 9 - 15
  • [29] Response to a Serogroup B Meningococcal Disease Case Among Military Trainees
    Marcus, Joseph E.
    Bennett, William N.
    Frankel, Dianne N.
    Kieffer, John W.
    Casey, Theresa M.
    Huston, Amanda E.
    Hintz, Courtney N.
    Keller, Alexander P.
    Smolka, Michael T.
    Sikorski, Cynthia S.
    Yun, Heather C.
    Dolan, Matthew J.
    Kiley, John L.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (05):
  • [30] Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines
    Villena, Rodolfo
    Safadi, Marco Aurelio P.
    Valenzuela, Maria Teresa
    Torres, Juan P.
    Finn, Adam
    O'Ryan, Miguel
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (05) : 1042 - 1057